Chinese Journal of Tissue Engineering Research ›› 2019, Vol. 23 ›› Issue (34): 5447-5453.doi: 10.3969/j.issn.2095-4344.1966

Previous Articles     Next Articles

Preparation and property study of sustained-release osteoinductive gel

Lü Dongmei1, Luo Yonghua1, Wan Xiaolong1, Zeng Chunyu1, Li Ling1, He Yun1, 2
  

  1. 1Orofacial Reconstruction and Regeneration Laboratory, Southwest Medical University, Luzhou 646000, Sichuan Province, China; 2Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Southwest Medical University, Luzhou 646000, Sichuan Province, China
  • Received:2019-06-24 Online:2019-12-08 Published:2019-12-08
  • Contact: He Yun, MD, Associate professor, Orofacial Reconstruction and Regeneration Laboratory, Southwest Medical University, Luzhou 646000, Sichuan Province, China; Department of Oral and Maxillofacial Surgery, Hospital of Stomatology, Southwest Medical University, Luzhou 646000, Sichuan Province, China
  • About author:Lü Dongmei, Master candidate, Orofacial Reconstruction and Regeneration Laboratory, Southwest Medical University, Luzhou 646000, Sichuan Province, China
  • Supported by:

    the National Natural Science Foundation of China, No. 11702231 (to HY); Sichuan Medical Association Program, No. S16079 (to HY); Human Resources and Social Security Department of Sichuan Province, No. 201864 (to HY); National Innovation and Entrepreneurship Training Program for Students, No. 201816032054 (to HY); Southwest Medical University Project, No. 2016014 (to HY)

PDF

86

Abstract:

BACKGROUND: Local application of sustained-release osteoinductive medicine to improve the healing of socket and reduce the absorption of alveolar bone after tooth extraction has been receiving increasing attention.
OBJECTIVE: To investigate the best ratio of each component of the poly(lactic-co-glycolic acid (PLGA) loaded sustained-release osteoinductive gel form the perspectives of the properties, coagulation time, viscosity of the gel and the cumulative drug release rate.
METHODS: The orthogonal design method was used to investigate the effect of N-methyl-2-pyrrolidone (NMP) to glycerol triacetate (GTA) ratio (5∶5, 6∶4, 7∶3, 8∶2, 9∶1), PLGA mass fraction (20%, 30%, 35%, 40%, 45%, 50%), and osteoinductive gel content on the properties, coagulation time and viscosity of the gel and the cumulative drug release rate. One-way analysis of variance was used to explore the differences among different groups in the viscosity and coagulation time of the gel. Two-way analysis of variance was used to explore the differences among different groups in the cumulative drug release rate.
RESULTS AND CONCLUSION: (1) When osteoinductive gel content was 10% and PLGA mass fraction was 20%, as NMP increased and GTA decreased, gel fluidity increased, coagulation time was shortened, coagulation hardness was reduced, viscosity was reduced, and the cumulative drug release rate during the same time was increased. The gel property and performance was encouraging when the NMP to GTA ratio was at 5∶5. (2) When the NMP to GTA ratio was at 5∶5, the volume fraction of osteoinductive gel was 10%, with the mass fraction of PLGA content increased, gel fluidity was reduced, coagulation time was shortened, viscosity was increased, and gel hardness was increased, the cumulative drug release rate during the same time was decreased. The gel property and performance was encouraging when GLGA content was 40%. (3) When the NMP to GTA ratio was at 5∶5, the volume fraction of osteoinductive gel was 40%, when the volume fraction of osteogenic inducer was greater than 20%, no coagulation occurred when the gel contacted with water. When the volume fraction of osteoinductive gel was less than 20%, coagulation time was similar between groups, gel was soft, and the cumulative drug release rate during the same time was decreased. When the volume fraction of osteoinductive gel was 15%, gel had an encouraging property and performance.

Key words: osteogenic inducer, PLGA, bone regeneration, sustained-release agent, socket healing, viscosity, coagulation time, drug carrier, release

CLC Number: